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Summary.-One hundred and sixteen human tumours were transplanted to
thymectomized, irradiated, antilymphocyte serum-treated mice. In 12 cases the
recipient mice died rapidly, presumably from infection. With the remaining 104
tumours, three-quarters grew to a varying extent, retaining the characteristic
histological features of the primary tumours. Implant nodules varied widely in
composition, from solid tumour and stroma to dense fibrous tissue without recogniz-
able tumour cells. There was no relation between degree of malignancy and ability
to grow, and also some benign tumours grew.
In 44 cases, mice were treated with the drug or drugs most likely to be used in
the patients and the effects on the implants were assessed histologically. Two
tumours were largely destroyed and one showed marked metaphase arrest. Three
other tumours showed lesser changes that were attributable to the drug but were of
equivocal significance.
There appeared to be differences in drug sensitivity between structurally different
clones of the same tumour, and some tumours treated with two alkylating agents
were damaged by one and not the other, suggesting that this model may have
substantial discriminatory power. Assays such as this should not be used to guide
treatment of the patient without prior validation. The practical and ethical diffi-
culties of validation by clinical trial may be insurmountable, and an alternative
approach to validation is proposed which does not raise these difficulties.
RELATIVELY FEW cancer patients bene-
fit substantially from chemotherapy as
practised at present. The majority show
little or no useful antitumour effect but
nevertheless suffer from the toxic effects
of the drugs they are given, and some-
times die from them. Yet some dozens
of drugs are available, each of which,
when given to patients with a variety
of tumours, produces prolonged objective
remissions in a small proportion. Un-
fortunately, there is as yet no way of
matching drug to tumour in advance of
treatment to ensure that each patient
receives the drug or drugs that are
optimally effective against his or her
tumour. Nor is it feasible to find this
out simply by trying drugs in turn,
because ineffective but toxic treatment
compromises subsequent treatment, and
because time is generally at a premium.
There is, therefore, a pressing need for
methods to determine the most effective
drug for an individual tumour using
biopsied material.
This problem may be approached by
observing the effects of drugs on tumour
cells grown in vitro or on tumours trans-
planted to laboratory animals. The diffi-
culties of using cells cultured in vitro
for this purpose may be summarized
as follows: (1) changes in metabolism
imposed by growth in culture media
may modify the effects of drugs; (2) in
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vitro experiments do not take into account
in vivo disposition and metabolism of
drugs; (3) rapid selection of particular
tumour cell clones adapted to growth in
vitro may occur, and these may be
unrepresentative of the tumour cell popu-
lation in vivo (Sheard, Double and Beren-
baum, 1971; Editorial, Lancet, 1972).
With these fundamental drawbacks,
it would be surprising if tissue culture
methods could be generally used to
assess the in vivo drug sensitivity of
individual tumours, although they might
well succeed in particular cases, for
instance, where sensitivity depended on
simple presence or absence of an enzyme.
Success is therefore more likely with the
more difficult but also more direct method
of assessing drug effects on tumours
transplanted into laboratory animals.
The purpose of this paper is to report
our experience in transplanting 116 human
tumours to immunosuppressed mice and
in treating 44 of them with chemothera-
peutic agents. The tumours used in the
work described here were transplanted
between November 1970 and March 1973.
Twenty-two other tumours were used in
earlier experiments in which the methods
described here were evolved, but these
tumours are not included in this series.
MATERIALS AND METHODS
Immunosuppression of mice.-Male or
female CBA mice, 6-10 weeks old, were
thymectomized under bromethol anaesthesia.
Antilymphocyte serum, prepared by the
method of Levey and Medawar (1966), was
inactivated at 56°C for 30 min, absorbed
once for 30 min at room temperature with
4% of its volume of packed mouse erythro-
cytes, sterilized by passage through a 0-2 /tm
pore size filter (Sartorius or Millipore) and
stored at -70°C. Mice were given 4 doses
of 0 5 ml serum subcutaneously on alternate
days, starting at least 4 days after thym-
ectomy, and were then given 300 rad whole
body irradiation in a Phillips Stabilipan
(27 rad/min, 240 kV, 1 mm Cu filter).
Mice were used for tumour implantation
within 3 weeks of irradiation, and 0-25 ml
antilymphocyte serum was given subcu-
taneously 3 times weekly from the time of
implantation until sacrifice.
Tumour implantation.-Tumours were
handled aseptically from the time of removal
from the patient. Any evidently normal
or necrotic tissue was removed, the tumour
minced finely in a small volume of Eagle's
Minimal Essential medium (British Drug
Houses Ltd) and 0-2 ml of tumour mince
was injected subcutaneously into the lateral
abdominal wall, usually within 2-3 h of
operation.
Ascitic fluids were centrifuged at 250 g
for 10 min and the deposit resuspended in
Eagle's medium for injection. Between 107
and 5 x 108 cells were injected.
The number of mice implanted with each
tumour depended on the amount of material
available. The mean number was 13 and
two-thirds of the tumours were implanted
into 5-15 mice each.
Chemotherapy.-The drugs used were
actinomycin D (Merck, Sharpe & Dohme),
chlorambucil (Burroughs Wellcome Ltd),
cyclophosphamide (Ward, Blenkinsop Ltd),
5-fluorouracil (Roche Products Ltd), mel-
phalan (Burroughs Wellcome Ltd), metho-
trexate (Lederle Laboratories Ltd), thiotepa
(Lederle Laboratories Ltd), trenimon (Bayer
Pharmaceuticals Ltd) and vincristine and
vinblastine sulphates (Eli Lilly & Co. Ltd).
All drugs were dissolved in saline except
chlorambucil, which was dissolved in arachis
oil, and melphalan, which was dissolved in
buffer provided by the manufacturer. Mel-
phalan and trenimon were dissolved immedi-
ately before administration. Actinomycin
D, cyclophosphamide and 5-fluorouracil were
dissolved not more than 2 h before adminis-
tration. Methotrexate solution was kept
up to 5 days and solutions of the remaining
drugs up to 2 weeks at 5°C.
All drugs were given intraperitoneally
except 5-fluorouracil, which was given sub-
cutaneously. All were given in a single
dose except methotrexate, which was given
in 5 daily doses. The volume of solvent in
all cases was such that each dose was given
in 0-1 ml volume per 10 g body weight.
The recipients of any one tumour were
divided into approximately equal-sized
groups, including one of untreated controls,
depending on the number of drugs to be
investigated. The mean group size was 6,
and for two-thirds of tumours the group
size lay between 5 and 15 mice. Drugs
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were given at various times between 5 and
33 days after implantation. Mice were
killed betw!een 2 and 15 days after treatment
and the implantation areas removed and
fixed in formol saline for histological examina-
tion. Details of drug doses and times of
administration and examination are given in
Table VII.
Sections of all implants from any one
tumour were randomized and examined
without knowledge of the treatment of the
recipient.
RESULTS
With 12 of the 116 tumours, all
implanted mice died within a few days
(Table II). Half of these were tumours
of the gastrointestinal tract and death
was presumably due to microbial con-
tamination and consequent overwhelming
infection of these heavily immunosup-
pressed animals. The results to be dis-
cussed therefore refer to the remaining
104 tumours.
Gross examination
Small nodules generally became pal-
pable in the implant area after 1-3 weeks.
They usually grew slowly and were about
1-5 mm in diameter when they were
excised, generally about 15-30 days after
implantation. Occasional tumours griew
more rapidly, attaining a diameter of
5-10 nmm within 3 weeks. The presence
of a palpable nodule, and even its pro-
gressive growth, was no guarantee of
growth of tumour tissue for, as described
below, some nodules consisted of fibrous
tissue or abscesses only.
Histological examination
Growth.-Implants were excised at
times varying from 7 to 104 days after
transplantation and histologically recog-
nizable tumour was found at all times
from 12 days onward. There was no
evident trend with time in the proportion
of successful implants (Table I), but the
data should be treated cautiously as
the timing of excisions was not random;
implants that failed to become palpable
N
Day excised i,
7-14
15-19
20-24
25-29
30-34
35-39
40-49
50-104
Total
(%o)
* Tables I-VI
therapy.
Iumber of
implants
34
230
152
79
33
31
36
37
632
(100)
Growth
0 + +-+
18 11 5
81 97 52
77 47 28
53 17 9
12 15 6
6 15 10
16 2 18
8 1 28
271 205 156
(43) (32) (25)
refer to mice not given chemo-
would tend to be excised after a few
weeks, so that there may have been a
progressive failure of implants not de-
tected by this manner of proceeding.
In the case of 14 tumours, sufficient
mice were implanted to allow repeated
examinations over spans of 8-64 days.
In 10 of these, tumour was present at all
times of examination and in 3 it was
absent at all times. In only 1 tumour
did the status of the recipient mice
change over such a time span (tumour
absent at 56 days and present at 77
days). It appears, therefore, that samp-
ling may be made at any convenient
time.
The implants varied greatly in the
extent to which they became established
and grew, and we graded this as follows:
+ + Good growth. One or more nodules,
generally 2-5 mm in diameter, but
sometimes 1 cm or more, consisting
either entirely of tumour tissue with
supporting stroma, or of tumour
tissue growing on the surface of and
within nodules of fibrous tissue, often
showing mitotic figures at least as
frequently as the primary tumour
(Fig. 4, 7, 11).
+ A small amount of microscopically
recognizable tumour tissue, generally
consisting of a few acini or clumps
of tumour cells, usually embedded
in fibrous tissue. Mitoses occasion-
TABLE I. Fate of Implants of Human
Tumours in Irnmnunosuppressed Mice*
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ally seen. These appearances are
compatible with either poor growth
or mere survival (Fig. 13).
O No tumour present. The implant-
ation site shows a dense fibrous
nodule, completely necrotic tumour,
an abscess lined with granulation
tissue or, infrequently, no abnormal
tissue at all.
Overall yrading
There was fair uniformity in the
fate of different implants of the same
tumour and, in more than half the cases,
all the implants of each tumour had the
same grade (0, + or ++). It was
therefore relatively easy to assign an
overall grade of 0, + or + + to each
tumour on the basis of the fate of its
implants. These grades are shown in
Tables II-VI which show that, in the
104 tumours the recipients of which
survived the first week after transplanta-
tion, growth was good in 35%0, poor in
39%0 and absent in 26%.
Structure. Tumours that grew,
whether well or poorly, usually retained
to a large extent the characteristic
histological appearance of the tumour in
the patient; squamous cell carcinomata
produced keratin, and ovarian and colonic
carcinomata produced mucin. Usually,
the nature of the primary tumour could
be determined without difficulty by exam-
ining the implants (Fig. 4, 11, 13). In-
deed, growth in mice occasionally enabled
the tumour type to be ascertained more
easily than did examination of the
primary if the sample obtained was
largely necrotic or where only ascitic
fluid was available. However, tumours
growing in mice often differed from their
primaries in some respects. For instance,
they sometimes showed a more solid
structure (Fig. 6, 7), and a greater
variety of tissues could sometimes be
identified in implants of a teratoma
than in the original specimen. Again,
the tendency of tumours to show varia-
tions in structure in different areas was
sometimes more striking in these implants.
In some cases, appearances suggested
that clearly different clones of tumour
cells were growing side by side (Fig.
10, 11).
Host response. Where little or no
tumour tissue survived, there was a
marked fibrous tissue reaction, usually
forming dense collagen by the time the
nodule was excised (Fig. 13). In tumours
that grew well there was less fibrous
tissue, but a thin connective tissue
capsule was usually present (Fig. 7). The
lack of cellular reaction round many
tumour implants was striking; where
cellular infiltrates were present, they
were light and consisted mainly of macro-
phages and/or polymorphonuclear leuco-
cytes. Occasional tumours showed small
peripheral collections of lymphocytes and
plasma cells. Lymph nodes removed
with the excised implant were invariably
depleted of lymphocytes and inactive.
Invasion.- Appearances suggestive of
invasion of surrounding tissues were rare.
Occasionally, clumps of tumour cells
were present in lymphatics near the
implant, one bladder carcinoma was seen
to invade muscle and in one ovarian
carcinoma deposits were present in the
omentum. However, in this last case it
is possible that the peritoneuim was
penetrated during the injection. The
finding of clumps of tumour cells in the
implant area not continuous with the
main mass of growing tumour is not in
itself evidence of spread as the injected
inoculum is a suspension of tumour
fragments which may be distributed fairly
widely during injection.
Relation between growth and tiumour type
and grade of malignancy
Tables II-VI shows that a third of
all tumours gave good growth and another
third survived or grew poorly. The best
results were given by melanomata good
growth was obtained with two-thirds of
tumours where the recipients survived
the first few days. No breast carcinomaTHE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE
TABLE II.-Overall Fate of Human Tumours in Immnunosuppressed Mice
Growth
Tumour type
Ovariani (see Table I1I)
Bladdler (see Table IV)
Melanoma
Gastrointestinal tract (see Table V)
Breast
Uterine carcinoma
Mliscellaneous (see Table VI)
Total
(o/ )
Total
Recipients
(liecd 0 + + +
35 0 7 17
20 0 5 8
16 2 1 4
12 6 1 2
9 1 2 6
4 0 0 2
20 3 11 2
116 12 27 41
(100) (10) (23) (35)
11
7
9
3
0
2
4
36
(31)
TABLE 11. Ovarian Tumours: Growth in
imnmunosuppressed Mice
Maliginant tumrouIrs
SerouS adenocarcinoma
Mulcinious a(lernocarcirnoma
Poorly differentiated a(lenio-
carcinoma
Enidometroid carcinoma
Granulosa cell carcinoma
Mesonephroid carcinoma
Dysgerminoma
Lipoidal cell tumnour
Endodermal sintus tumour
Teratoma
Total
Benigni tumours
Fibroma
Mucinous cystadenoma
Serous cysta(lenoma
Brenner tumouir
Teratoma
Total
Growth
Total 0 + ++
12 0 6 6
6 1 4 1
2 0 2 0
1
I
28
2
2
1
1
7
0
0
0
1
l
0
4
1 1
0
0
3
1
0
1
0
0
0
0
14
1
0
1
0
3
1
1
0
0
0
0
1
10
0
0
0
0
1
grew well, but most survived or grew
poorly for at least 3-7 weeks.
With sarcomata it was difficult to
decide whether transplantation was suc-
cessful for in many cases their structure
was not distinguishable with confidence
from reactively proliferating host con-
nective tissues. Accordingly, except in
the case of one uterine leiomyosarcoma
which grew well and showed frequent
mitotic figures, we could not positively
identify tumour tissue in implants of
any of the few sarcomata we examined
(Table VI).
There was no evident relation between
degree of malignancy and ability to grow
in recipient mice. This point is illustrated
by the 20 transplanted bladder carcino-
mata that were graded histologically
(Table IV). Similarly, good, poor and
no growth occurred indiscriminately
among ovarian carcinomata that varied
from well differentiated to anaplastic,
and 4 out of 7 benign ovarian tumours
also grew (Table III).
Serial transfer
Serial passage oftumours was attempt-
ed in 3 cases only, and succeeded in all.
A papillary adenocarcinoma of the ovary
that had been growing in mice for 60
days was passaged in secondary recipients
for 77 days and in tertiary recipients for
42 days. An ovarian teratoma was pas-
saged after 104 days and the secondary
transplants maintained for a further 126
days. A gastric carcinoma transferred
after 66 days was maintained for a
further 98 days. In all cases tumour
was growing well when the experiments
TABLE IV. Bladder Tumours: Growth in
Immunosuppressed Mice
Growth
Total 0 + + +
Transitional cell carcinomata
Gradle I
Grade II
Gradle III
Grade IV
Squamous cell caicinoma
Total
4
5
3
7
0
1
0
3
3
3
1
1
1
2
3
1 1 0 0
20 5 8 7
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TABLE V.-Gastrointestinal Tract Tumours: Growth in Immunosuppressed Mice
Growth
Recipients ,
Total died 0 + + +
Carcinoma oesophagus 4 3 0 1 0
Carcinoma stomach 2 1 0 0 1
Carcinoma colon 2 1 0 0 1
Adenocarcinoma salivary gland 1 1 0 0 0
Squamous cell carcinoma parotid 1 0 0 0 1
Squamous cell carcinoma oropharynx 2 0 1 1 0
Total 12 6 1 2 3
TABLE VI.-Miscellaneous Tumours: Growth in Immunosuppressed Mice
Growth
Recipients
Total died 0 + ++
Leiomyosarcoma uterus 2 0 1 0 1
Lymphosarcoma 2 1 1 0 0
Reticulosarcoma 1 0 1 0 0
Medulloblastoima 2 0 2 0 0
Neuroblastoma 2 0 2 0 0
Testicular teratoma (malignant) 2 0 0 0 2
Adenocarcinoma nasal antrum 1 1 0 0 0
Wilm's tumour 1 1 0 0 0
Bronchial carcinoid 1 0 1 0 0
Origin unknown
Carcinoma, deposit in omentum 1 0 0 0 1
Malignant ascites 5 0 3 2 0
Total 20 3 11 2 4
FiG. 1. Tumour 5. Ovarian serous cystadenocarcinoma 17 days after implantation.
H. & E.x450.aV
FIG. 2. Tumour 5, 17 days after implantation and 3 days after treatment with chlorambucil,
5 mg/kg. Appearances are not significantly different from those of the untreated tumour (Fig. 1).
H. & E. x450.
aFIG. 3. lumour 5, 17 days after implantation and 3 days after treatment with cyclophosphamide,
200 mg/kg. Marked metaphase arrest. H. & E. x 450.20 M. C. BERENBAUM, C. E. SHEARD, J. R. REITTIE AND R. V. BUNDICK
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were discontinued. There would there-
fore seem to be little difficulty in serially
transplanting tumours that grow well
in the first instance, as noted also by
Cobb (1973) and Detre and Gazet (1973).
Effects of chemotherapy
In 44 cases implanted mice were
treated with the drug or drugs indicated
by the clinician as most likely to be
used in the patient if chemotherapy
proved necessary (Table VII).
It was not possible to assess the effects
of chemotherapy by measuring tumour
diameter or weighing the excised tumour
because the nodules were usually small,
grew slowly, contained widely varying
amounts of fibrous tissue and could not
be distinguished by palpation from no-
dules of fibrous or necrotic tissue or
abscesses. Accordingly, assessment was
made by histological examination of
randomized coded slides. The results are
shown in Table VII.
In the majority of tumours, chemo-
therapy had no evident effect, the ap-
pearance of treated tumours being within
the range of variation of that seen in
untreated tumours. In 3 cases, an un-
equivocal effect was seen:
(1) Tumour 5. This was a poorly
differentiated serous cystadenocarcinoma
of the ovary with frequent mitotic
figures, which grew well in recipient
mice (Fig. 1). Three days after treatment
with cyclophosphamide, 200 mg/kg body
weight, there was a conspicuous meta-
phase arrest (Fig. 3). In contrast, treat-
ment with chlorambucil, 5 mg/kg, had
no discernible effect (Fig. 2).
(2) Tumour 42.-This was a squamous
cell carcinoma of the parotid which grew
well in recipient mice, showing a typical
structure and producing keratin (Fig. 4).
Two weeks after giving cyclophosphamide,
100 mg/kg, only small fragments of
tumour remained, consisting largely of
keratinized cells, and surrounded by
fibrous tissue infiltrated with polymorphs
(Fig. 5).
(3) Tumour 43. This was an omental
metastasis of a poorly differentiated.
pleomorphic carcinoma, with frequent
mitoses. It was of unknown origin (Fig.
6). Two weeks after giving chlorambucil,
5 mg/kg, the only evidence of residual
tumour was a few giant cells with
vacuolated cytoplasm that were probably
damaged tumour cells (Fig. 8). The
remainder of the excised nodules con-
sisted of fibrous or necrotic tissue in-
filtrated with polymorphonuclear leuco-
cytes and plasma cells (Fig. 9). Tumours
in untreated mice continued to grow well
(Fig. 7).
In 3 other cases lesser effects were
seen. These occurred in all or the
majority of treated mice and not in the
controls, and could reasonably be attri-
buted to drug action. These changes
were: (1) excessive numbers of tumour
giant cells in a melanoma (tumour 20)
treated with melphalan (Fig. 11, 12);
(2) increased numbers of pyknotic nuclei
in a melanoma (tumour 23) after treat-
ment with melphalan but not with
cyclophosphamide; and (3) squamous
metaplasia in a bladder carcinoma (tumour
32) after treatment with methotrexate
(Fig. 13, 14). The significance of such
changes is not clear and they must be
regarded as equivocal until the subsequent
fate of tumours that show them is
known.
In a melanoma (tumour 20) that
consisted of structurally different clones,
these appeared to differ in their drug
susceptibility, i.e. a drug effect was seen
in one clonal type, but not in an adjacent
clone of different types (Fig. 11, 12).
D)ISCUSSION
This investigation shows that hunan
tumours can be grown with fair regularity
in thymectomized, irradiated, ALS-treated
mice. In our hands two-thirds of all
tumours survived or grew, sometimes for
months. If tumours are excluded the
recipients of which died withiii a fewTHE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE 23
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FIG. 6. Tumour 43, carcinomatous secondary in omentum, origin unknown. Original tumour.
H.&E. x108.
FIG. 7. Tumour 43, 19 days after implantation. .Note solicI structure comparea wirn primary
tumour (Fig. 6). H. & E. x 108.THE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE
FIG. 8. Tumour 43, 19 days after implantation and 14 days after treatment with chlorambucil,
5 mg/kg. A small nodule of tumour giant cells, surrounded by fibrous tissue infiltrated with
polymorphs and plasma cells, is the only remnant of the tumour. H. & E. x 45.
FIG. 9. As Fig. 8, showing complete destruction ofthe remainder ofthe tumour. H. & E. x 108.
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FiG. 10. Tumour 20, melanoma, showing primary tumour. H. & E. x 108.
days, presumably from infection, about
three-quarters of the tumours (and 60%
of implants) survived or grew. These
results are appreciably better than those
obtained on primary transplantation to
the cheek pouch of the cortisone treated
hamster, where some 16-45% of tumours
survived or grew (Handler, Davies and
Sommers, 1956; Patterson, Patterson and
Chute, 1957; Patterson, 1968; Williams,
Evans and Blamey, 1971) or to thym-
ectomized, ALS-treated,unirradiatedmice,
in which about a quarter do so
(Phillips and Gazet, 1970). Comparable
results (about two-thirds successful trans-
plants) were obtained by Castro (1972)
who implanted tumours beneath the
kidney capsule of thymectomized, irradi-
ated, bone marrow-reconstituted mice.
Cobb (1972) transplanted human tumours
either subcutaneously or into the cheek
pouch of thymectomized, ALS-treated
hamsters. About halfthe subcutaneously
implanted tumours and 80% of those
placed in the cheek pouch grew locally.
However, the proportion of successful
implants was low so that when growth
was obtained it was usually observed in
only 1 or 2 recipients in an average
group of 5. It was interesting that the
majority of tumours metastasized to the
lungs, even when they did not grow at
the implantation site. It is unlikely
that the optimum conditions for growing
human tumours in xenogeneic hosts have
been foundyet, and systematic comparison
of various species and host treatments is
required. Nude mice may prove useful
for this purpose (Rygaard and Povlsen,
1969; Povlsen and Rygaard, 1971; Povlsen
et al., 1973), particularly ifproblems ofsup-
ply and short life span can be overcome.
In successfully transplanted tumours
the characteristic histological appearances
are generally retained to a striking
extent, as has been noted by many other
workers (Handler et al., 1956; Patterson,
1968; Williams et al., 1971; Castro,
1972; Cobb, 1972, 1973). This suggests
that many of the biochemical featuresTHE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE
FIG. 11. Tumour 20, 19 days after implantation, showing structurally different clones of tumour
cells. H. & E. x 180.
BIG. 12.-Tumour 20, 19 days after implantation and 14 days after treatment with melphalan, 2-5
mg/kg, showing formation of tumour giant cells in one clone and no evident change in the other.
H.&E. x180.
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1.THE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE
of the original tumour are also retained,
for a marked change in these would not
be consistent with retention of morpho-
logical characteristics and such differ-
entiated functions as production of mucin
and keratin. It is also relevant that
continuing endocrine function is shown
by human choriocarcinoma and para-
thyroid adenoma tissue transplanted to
immunosuppressed hamsters, rats and
mice (Hertz, 1959; Castro and Zanelli,
1973), and continued production of im-
munoglobulin and virus antigen by Bur-
kitt's lymphoma tissue transplanted to
nude mice (Povlsen et al., 1973). These
findings encourage the hope that the
drug sensitivity of the original tumour
is also retained to a useful extent, a
supposition supported by our finding
that, when a rat tumour of known drug
sensitivity was grown in immunosup-
pressed mice, the rank order of effective-
ness of 4 drugs was identical in the
species of origin and in the xenogeneic
host (Sheard et al., 1971).
This model therefore may be a suitable
one in which to investigate the drug
sensitivity of individual human tumours.
However, caution is required in view of
the finding of Cobb (1973) and Detre and
Gazet (1973) that the frequency of mitoses
in human tumours examined some months
after transplantation to immunosuppres-
sed mice was usually higher than in the
primary tumour. It is not known whether
this was due to these relatively small
tumour masses being better vascularized
than the larger primaries from which
they were derived, or whether selection
of rapidly growing cells had occurred
during the 3-8 months sojourn in the
xenogeneic host.
There are practical difficulties in
determining the drug sensitivity oftumour
transplants. Because ofthe varying com-
position of the implant nodules, methods
of assessment that are not histological
must always be accompanied by careful
histological examination, but this is a
relatively crude method of evaluation
which may fail to reveal some important
types of drug-induced damage. On the
other hand, changes may be seen, the
significance of which is difficult to assess
and which may be unimportant in the
long run. Because of these difficulties,
and the additional problem of sampling
error, we adopted stringent criteria in
evaluating the changes we saw. In only
3 of the 44 transplanted tumours we
treated did we feel confident in describing
the damage as severe, that is, we would
have expected a marked objective response
to occur if such changes had been seen
in a treated patient. Another 3 tumours
showed lesser damage, the significance of
which could not be assessed in the absence
of serial studies.
In practice, it is the difficulty of
determining the effect of the drug on the
tumour in the patient rather than in the
recipient mouse, that is likely to present
the greater problem. In only a minority
of tumours in patients is direct measure-
ment possible during therapy, repeated
biopsies are rarely justifiable and in most
patients surgery and/or radiotherapy are
also used and their timing often makes
it impossible to assess the effect of
chemotherapy alone.
Two findings call for particular com-
ment. First, tumour 5 showed marked
damage to the mitotic apparatus after
treatment with cyclophosphamide but
was apparently unaffected by chlor-
ambucil (Fig. 2, 3), and tumour 23
showed increased numbers of pyknotic
nuclei after melphalan but not after
cyclophosphamide. Second, some tumour
implants showed histologically different
clonal types and in at least one of these
(tumour 20) the clones appeared to
differ in sensitivity to melphalan, at
least as shown by structural changes
after drug administration (Fig. 11, 12).
These differences in effect between 2
agents of the same class acting on the
same tumour, and between different
clones of the one tumour, suggest that
this model shows substantial discrimina-
tion and supports the belief that the
changes observed are not therapeutically
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irrelevant or nonspecific but do indeed
reflect tumour drug sensitivity.
Other workers have also shown that
human tumours growing in xenogeneic
hosts may be damaged by chemothera-
peutic agents. These studies have mainly
involved later generations of repeatedly
passaged tumours which have been shown
to be sensitive to a variety of agents
(Hertz, 1960; Friedell, Sherman and
Sommers, 1961; Kaufman and Lich-
tenauer, 1968; Adams et al., 1972). How-
ever, the extent to which such repeatedly
transplanted tumours retain their initial
drug sensitivity is unknown. Smith
(1969) found that first generation implants
of human tumours in the hamster cheek
pouch varied in sensitivity to metho-
trexate and nitrogen mustard, and sug-
gested that this variation implied varying
drug sensitivities in the original tumours.
However, as the latter sensitivities were
not known, such a relationship could not
be ascertained.
The only study so far that has been
addressed directly to the problem of
comparing the drug sensitivity of a
transplanted tumour with that of the
primary is that of Burt et al. (1966),
who describe a patient with a carcinoma
of the bladder that was sensitive to
5-fluorouracil and x-rays and resistant
to vinblastine and that retained these
characteristics when grown in immuno-
suppressed hamsters. This correspond-
ence in a single patient is encouraging,
but it is evident that any assay intended
for use in determining the drug sensitivity
of individual human tumours should be
validated in a statistically significant
manner in a reasonable number of
patients.
Two approaches to validation of such
an assay may be considered. The assay
would be validated if, for example, the
results of chemotherapy in patients re-
ceiving drugs indicated by the assay were
significantly better than those in com-
parable patients receiving drugs according
to currently accepted criteria and without
assay. This approach appears simple in
theory but would be exceedingly difficult
in practice. There is a wide variation
in the results of chemotherapy obtained
by different clinical units and from one
period to another in the same unit,
due largely to uncontrollable factors such
as acquisition of expertise and the great
inherent variability of cancer patients
and their responses to treatment. It is
therefore not warrantable simply to com-
pare results obtained before the assay is
adopted by a particular unit with those
obtained afterwards, nor to compare the
results obtained by units using the assay
with those of units not using it. Unless
the improvement in results following
adoption of the assay was so great that
the role of such uncontrolled variables
could be discounted, a properly designed
prospective trial would be needed, in
which the 2 groups of patients were
randomized from the same intake and
treated contemporaneously by the same
personnel, to show whether use of the
assay influenced the results of chemo-
therapy. Such a trial would be a formid-
able undertaking and, for ethical reasons,
it could only involve clinicians who did
not believe that a deliberate choice of
drug based on personal experience and
knowledge was likely to be better than
a choice based on an unvalidated
laboratory assay.
These difficulties are probably in-
superable and consequently the tempta-
tion to allow such laboratory assays to
influence the choice of drug before they
are thoroughly validated is not always
resisted. Unfortunately, the incorpora-
tion of an unvalidated method into
regular practice can make it very difficult
later to carry out the sort of unbiased
investigation that alone can determine
the usefulness or otherwise of the
method.
We therefore propose an alternative
approach, briefly outlined earlier (Beren-
baum and Sheard, 1972) based on the
following considerations. On the whole,
clinicians tend to treat most patients
with a particular type of tumour withTHE GROWTH OF HUMAN TUMOURS IN IMMUNOSUPPRESSED MICE 31
one or a few drugs shown by experience
to be beneficial in a useful proportion
of cases. Tumours of a particular type
generally show a spectrum of sensitivity
to any one drug and, in any individual
patient, the drug may produce anything
from complete remission to no benefit
whatsoever. The effects of treating
human tumours transplanted to mice
also vary, as we have shown here, from
severe damage to none. In principle, it
should not be difficult to determine
whether the relatively few tumours that
are markedly damaged in the mouse
show a statistically satisfactory corres-
pondence with the few where the patient
has benefited markedly from the same
drug. If this proves to be the case, the
assay will be validated. Accordingly, the
choice of drugs to be used in individual
patients is left entirely to the clinician
and the effects of these drugs only are
assayed on the same tumours. The
results of assaying the effects ofdrugs that
the patient does not receive are irrelevant,
for such assays cannot be validated.
However, in those cases in which no
choice of drug has been made at the
time of assay, the 2 or 3 drugs most
likely to be used are tested.
If the assay is validated it can then
be used predictively, in the first instance
to detect patients whose tumours are
likely to show substantial regression under
treatment with the drug in question.
If it appears that the assay is valid for a
variety of drugs, the logical next step
would be to modify it to find which drug
out of those available would be most
suitable for use in an individual patient.
There are no ethical difficulties in this
approach and it can be effected con-
comitantly with orthodox treatment.
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